Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Histogenics Cp (HSGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,493
  • Shares Outstanding, K 62,025
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,410 K
  • 60-Month Beta 3.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.69
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/21/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +76.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.11 +9.82%
on 03/15/19
0.20 -41.07%
on 03/19/19
-0.01 (-7.08%)
since 02/22/19
3-Month
0.08 +51.00%
on 01/02/19
0.28 -56.70%
on 01/03/19
-0.35 (-74.30%)
since 12/21/18
52-Week
0.08 +51.00%
on 01/02/19
3.05 -96.04%
on 06/15/18
-2.77 (-95.82%)
since 03/22/18

Most Recent Stories

More News
Biotech and Cannabis Stocks That Are Emerging

HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, is developing a...

ACB : 9.03 (-5.64%)
GWPH : 168.83 (-4.07%)
CRMD : 1.65 (-1.20%)
HSGX : 0.12 (-4.96%)
Jonathan Lieber Joins Danforth Advisors as Managing Director

Danforth Advisors, LLC, a consulting firm providing operational accounting and finance support, together with CFO services, for private and public life science companies, today announced the appointment...

HSGX : 0.12 (-4.96%)
Is Histogenics (HSGX) Outperforming Other Medical Stocks This Year?

Is (HSGX) Outperforming Other Medical Stocks This Year?

HSGX : 0.12 (-4.96%)
Best Ways to Play Biotech Rally

HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of this bearish...

CLDX : 4.94 (-3.89%)
GNMX : 0.21 (-4.34%)
GERN : 1.69 (-7.65%)
DCTH : 0.2650 (-7.02%)
HSGX : 0.12 (-4.96%)
The Next Big Biotech Breakout

HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data...

GNMX : 0.21 (-4.34%)
ENDV : 0.0179 (-3.24%)
CELGZ : 1.25 (-0.80%)
HSGX : 0.12 (-4.96%)
BMY : 48.16 (-1.55%)
AXSM : 13.00 (-1.81%)
Histogenics and FDA Conclude Discussions Regarding NeoCart(R) Phase 3 Clinical Trial Data and Regulatory Pathway

Histogenics Corporation (Histogenics) (Nasdaq: HSGX), today provided an update on the NeoCart regulatory pathway based on discussions with the U.S. Food and Drug Administration (the FDA). Based on the...

HSGX : 0.12 (-4.96%)
Histogenics and FDA Continue to Discuss NeoCart(R) Phase 3 Clinical Trial Data and Potential Regulatory Pathway

Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on...

HSGX : 0.12 (-4.96%)
New Research Coverage Highlights Intersections, PRGX Global, Ecology and Environment, Histogenics, SeaChange International, and TransAct Technologies -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Intersections, Inc. (NASDAQ:INTX),...

GLEC : 0.0025 (unch)
SEAC : 1.37 (-0.72%)
PRGX : 8.09 (-2.29%)
EEI : 10.87 (-1.72%)
TACT : 8.70 (-1.97%)
INTX : 3.67 (unch)
HSGX : 0.12 (-4.96%)
Histogenics: 1Q Earnings Snapshot

WALTHAM, Mass. (AP) _ Histogenics Corp. (HSGX) on Thursday reported a loss of $14.8 million in its first quarter.

HSGX : 0.12 (-4.96%)
Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results

â?' Top-line Superiority Data from NeoCart Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third Quarter of 2018 â?'

HSGX : 0.12 (-4.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade HSGX with:

Business Summary

Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 0.13
1st Resistance Point 0.13
Last Price 0.12
1st Support Level 0.12
2nd Support Level 0.11

See More

52-Week High 3.05
Fibonacci 61.8% 1.92
Fibonacci 50% 1.56
Fibonacci 38.2% 1.21
Last Price 0.12
52-Week Low 0.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar